| abstract |
There is provided a pharmaceutically acceptable salt, specifically L-tartrate salt, as an extramedullary potassium outer layer potassium channel (ROMK) inhibitor, and crystalline form I and crystalline form II thereof. Pharmaceutically acceptable salts of ROMK inhibitors, in particular L-tartrate, have improved bioavailability and stability. |